ArticleMolecular oncology2020
Towards a cancer mission in Horizon Europe: recommendations.
Article in Molecular oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 44 citations in OpenAlex.
- Coercivity-Size Map of Magnetic Nanoflowers: Spin Disorder Tunes the Vortex Reversal Mechanism and Tailors the Hyperthermia Sweet Spot.Small science · 2026Article
- Aligning awareness, systems and policy to increase equitable access to genomically driven cancer care.BMJ oncology · 2026Review
- Patient and public involvement in basic and clinical psychiatric research: a scoping review of reviews.BMC psychiatry · 2025Article
- Describing the Core Attributes and Impact of Comprehensive Cancer Centers Internationally: A Chronological Scoping Review.Cancers · 2025Review
- Models of care and associated targeted implementation strategies for cancer survivorship support in Europe: a scoping review protocol.BMJ open · 2025Article
- Academia and society should join forces to make anti-cancer treatments more affordable.Molecular oncology · 2024Review
- From the creation of the European research area in 2000 to a Mission on cancer in Europe in 2021-lessons learned and implications.Molecular oncology · 2024Article
- Article
- Mapping the European cancer prevention research landscape: A case for more prevention research funding.European journal of cancer (Oxford, England : 1990) · 2023Article
- Engaging European society at the forefront of cancer research and care: How discussions at the 5Molecular oncology · 2023Article
- Profile of the multicenter cohort of the German Cancer Consortium's Clinical Communication Platform.European journal of epidemiology · 2023Article
- P53 Gene Expression and Nitric Oxide Levels after Artemisinin-Caffeine Treatment in Breast, Lungs and Liver of DMBA-Induced Tumorigenesis.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Article
- Palliative oncology and palliative care.Molecular oncology · 2022Article
- Cancer outcome research - a European challenge Part II: Opportunities and priorities.Molecular oncology · 2022Review
- Future care for long-term cancer survivors: towards a new model.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Article
- Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe.Journal of personalized medicine · 2022Article
- In the spotlight: Julio Celis, the Founding Editor of Molecular Oncology.Molecular oncology · 2022Article
- The Porto European Cancer Research Summit 2021.Molecular oncology · 2021Article
- Challenges and solutions to embed cancer survivorship research and innovation within the EU Cancer Mission.Molecular oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
41 authors at 20 institutions in 15 countries.
Funding
Abstract
A comprehensive translational cancer research approach focused on personalized and precision medicine, and covering the entire cancer research-care-prevention continuum has the potential to achieve in 2030 a 10-year cancer-specific survival for 75% of patients diagnosed in European Union (EU) member states with a well-developed healthcare system. Concerted actions across this continuum that spans from basic and preclinical research through clinical and prevention research to outcomes research, along with the establishment of interconnected high-quality infrastructures for translational research, clinical and prevention trials and outcomes research, will ensure that science-driven and social innovations benefit patients and individuals at risk across the EU. European infrastructures involving comprehensive cancer centres (CCCs) and CCC-like entities will provide researchers with access to the required critical mass of patients, biological materials and technological resources and can bridge research with healthcare systems. Here, we prioritize research areas to ensure a balanced research portfolio and provide recommendations for achieving key targets. Meeting these targets will require harmonization of EU and national priorities and policies, improved research coordination at the national, regional and EU level and increasingly efficient and flexible funding mechanisms. Long-term support by the EU and commitment of Member States to specialized schemes are also needed for the establishment and sustainability of trans-border infrastructures and networks. In addition to effectively engaging policymakers, all relevant stakeholders within the entire continuum should consensually inform policy through evidence-based advice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.